Key contacts

Will Corkill

Will Corkill
Director

Simon Wilson

Simon Wilson
Director

Regional office - Australia
Level 25
Aurora Place
88 Phillip Street
Sydney
NSW 2000
Australia
Tel: +61 (0)2 9258 1161

Regional office - New Zealand
Level 15
171 Featherston Street
Wellington 6011
New Zealand
Tel: +64 (0)4 8948555

swilson@edisongroup.com
wcorkill@edisongroup.com

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
Sealegs Corporation Kreuz Holdings
See more

Latest research

Alkane Resources

Major zirconium agreement signed for DZP

Flash note | Mining | 16/08/2016

Alkane Resources has signed an exclusive worldwide marketing, sales and distribution agreement with UK based specialist chemicals firm, Minchem, for its entire annual DZP zirconium output. The agreement is valid for an initial five-year period (with an option to extend for a further five) from the start of production by mutual agreement. We consider this a major key de-risking event that should provide key assurances for project financing.

Cradle Resources

Tantalising...

Initiation | Mining | 11/08/2016

In Panda Hill, Cradle has a 50% interest in a unique niobium asset in Tanzania. Not only its geology, but also the majority of its metallurgy is entirely conventional. As such, it is poised to become only the fourth mine in the world to produce a metal so unique that its price did not fall during the 2008/09 global financial crisis. Niobium is deemed ‘strategic’ by the US and ‘critical’ by the EU. Moreover, it is almost the only metal in the world in which China’s consumption…

Sealegs Corporation

Termination of coverage

Update | Engineering | 03/08/2016

Edison Investment Research is terminating coverage on Sealegs (SLG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

MMG

Termination of coverage

Update | Mining | 03/08/2016

Edison Investment Research is terminating coverage on MMG (1208). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Prima BioMed

The leader in LAG-3

ADR Outlook | Pharmaceutical & healthcare | 01/08/2016

Prima BioMed has progressed to the final stage of dose selection for its Phase IIb trial of IMP321 in breast cancer, and is on track to commence randomization in Q416. IMP321 is a soluble LAG-3 fusion protein that doubled tumor response rates in Phase IIa. Separately, partner Novartis has expanded its Phase I LAG-3 program in solid tumors and GSK plans to move its partnered autoimmune drug into Phase II this year. With the company’s development of in-house and partnered LAG-3 programs on track,…

About

Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports